About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
- 2014 Rate Card & Production Specs
- 2013 Rate Card & Production Specs
- Advertising Due Dates
- BPA Statement
Statement of Purpose
Guidelines for Authors
Health care professionals must consider drug-related adverse events along with efficacy when they prescribe medications. In explaining such concepts as statistical significance and magnitude of effect, the author suggests how indirect comparisons of studies can be used to help guide treatment decisions, especially if patients are taking other agents and combination therapy.
Stephen V. Faraone, PhD
Presentations included voreloxin for acute myelogenous leukemia; azacytidine (Vidaza) and decitabine (Depo-Cyt) for myelodysplastic syndromes; lenalidomide (Revlimid) for lymphoma; and dasatinib (Sprycel), nilotinib (Tasigna), and other investigational agents for chronic myelogenous leukemia.
Marvin M. Goldenberg, PhD, RPh, MS
Fourth Annual Ophthalmic Drug Development and Delivery Summit
Third Annual Onmark National Payor/Provider Forum
Topics discussed at the ophthalmic meeting included medications for dry eye and for diabetes-related conditions. The Onmark Forum focused on the anticipated need for collaboration between oncologists and adjunctive personnel because of a workforce gap; online information gathering; and standardizing procedures.
Continuing Education Credit
Obesity can have deleterious effects on health, often leading to diabetes and cardiovascular disease. Bariatric surgery, diet and behavior modification, and current and investigational drug therapies are some of the tools that are available now to help the overweight patient population.
Sarah R. Erlanger, PharmD, and Emily A. Henson, PharmD
David Nash, MD, MBA, discusses Pharmaceutical Industry Profile 2008, which documents the growth in spending and in product development by drug companies during the past two years.
David Nash, MD, MBA
Matthew Grissinger, RPh, FASCP, explains how hospital workers can prevent tragic outcomes by carefully labeling all medication containers and solutions.
Matthew Grissinger, RPh, FASCP
Stephen Barlas discusses new rules that might allow consumers to sue pharmaceutical companies in state courts over drug labeling.
From Banzel to Vimpat, P&T presents the latest FDA approvals, new indications, recalls, and industry updates.
Authors Yero and Rey review tetrabenazine (Xenazine) for Huntington’s chorea.
Tatiana Yero, PharmD, BS, and Jose A. Rey, PharmD, BCPP